GlassScriptPhysician profile
Darrell R Mease
NPI 1952377442
$2,432.07
in general payments reported to CMS, 2019-2025
34 companies · $502 in 2025
The $502 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,022 · 2020: $338 · 2021: $198 · 2022: $32.36 · 2023: $76.94 · 2024: $263 · 2025: $502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $842.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $842.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $271.53 | 2019-2025 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $270.87 | 2019-2021 | |
| Astellas Pharma US INC | $192.15 | 2019-2021 | |
| Novo Nordisk INC | $165.37 | 2019-2023 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $148.87 | 2019-2021 | |
| Abbvie INC. | $108.59 | 2024-2025 | |
| Sunovion Pharmaceuticals INC. | $108.44 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.66 | 2019-2023 | Jardiance |
| Sumitomo Pharma America, INC. | $105.99 | 2024-2025 | Gemtesa |
| Avanir Pharmaceuticals, INC. | $97.32 | 2019-2020 | |
| Mylan Specialty L.P. | $94.93 | 2019-2024 | Yupelri |
| Merck Sharp & Dohme LLC | $87.66 | 2024 | Verquvo |
| Allergan, INC. | $75.14 | 2019-2020 | |
| Pfizer INC. | $68.52 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $53.90 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $49.89 | 2024-2025 | Fanapt |
| Ucb, INC. | $43.91 | 2019-2020 | |
| Smith+Nephew, INC. | $40.33 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $36.53 | 2019-2023 | |
| Sk Life Science, INC. | $32.03 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $25.19 | 2019-2024 | Uzedy |
| Lundbeck LLC | $23.97 | 2023 | Rexulti |
| Lilly USA, LLC | $23.53 | 2025 | Mounjaro |
| Exact Sciences Corporation | $22.91 | 2025 | Cologuard Collection Kit |
| Viatris Specialty LLC | $21.73 | 2025 | Yupelri |
| Medtronic, INC. | $21.11 | 2025 | Interstim |
| Takeda Pharmaceuticals U.S.A., INC. | $19.34 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $19.18 | 2024 | Dupixent |
| Opko Pharmaceuticals, LLC | $18.57 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $17.47 | 2024 | Nuedexta |
| Axsome Therapeutics, INC. | $16.10 | 2025 | Auvelity |
| Zyla Life Sciences, INC. | $15.36 | 2019 | |
| Supernus Pharmaceuticals, INC. | $14.38 | 2022 | |
| Phathom Pharmaceuticals, INC. | $13.60 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darrell Mease listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.